An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal.

Slides:

Advertisements

Similar presentations

THE GENETIC OF CANCER Increased mitosisTumor formation Tumor suppression gene Hyperactive growth TranslocationPoint mutationAmplification Normal growth.

Advertisements

KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.

Progress in Cancer Therapy Following Developments in Biopharma

Schema for a human microbiome study

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Inhibitor of MAP kinase activation blocks colon cancer growth

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Figure 1 Current treatments for PNETs

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Possible combination therapies CDK4/6 inhibitors

The PI3K/Akt signalling and its activation in cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The hallmarks of adenovirus infection

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Schematic diagram of antibody drug conjugate

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Antigen-induced regulatory T cells

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 3 Defects in the T cell receptor signalling pathway

Figure 6 Combination therapy for HCC

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

Figure 4 Oncogenic KRAS and inflammation

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

(A) An overview of the JAK/STAT signalling pathway.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Molecular approaches to HER2 targeted therapy

Figure 1 Exosomes with siRNAs targeting

The Increasing Diversity of KRAS Signaling in Pancreatic Cancer

Model of the function of TBX2 in RMS.

Figure 2 from Sancho et al.

The cancer stem cell concept in cancer progression and metastasis

Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.

The putative genomic evolution of prostate cancer from normal epithelium to castrate-resistant, metastatic cancer Figure 2 from Mitchell and Neal British.

Figure 1 from B Zhu British Journal of Cancer (2015) 112, ; doi: /bjc

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

JAK3 Specific Kinase Inhibitors: When Specificity Is Not Enough

Nat. Rev. Clin. Oncol. doi: /nrclinonc

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

A hypothetical scheme targeting autophagy for glioblastoma sensitisation during radio-chemotherapy with TMZ Figure 1 from Michael I Achilleas G and.

Nat. Rev. Urol. doi: /nrurol

Figure 2 Site of action of checkpoint inhibitors and agonists being

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway

Figure 1 from M Holderfield

Molecular features of the colon during homeostasis and carcinogenesis

Figure 1 from T Schenk et al.

Nat. Rev. Endocrinol. doi: /nrendo

Fbxw7 ablation in LICs for CML sensitises the cells to imatinib by preventing quiescence. Figure 2 from S Takeishi British Journal of Cancer (2014) 111,

HDACs class I, II, IV mutations in human cancer

In melanoma tumours expressing the BRAFV600E oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.

Figure 1 Mechanisms of action of immunotherapy modalities

Mitochondrial priming model

Nat. Rev. Cardiol. doi: /nrcardio

Spectrum of cellular processes regulated by AXL activity

Figure 1 from D’Incalci et al.

Involvement of actin cytoskeletal reorganisation in EMT

The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Target antigens for ADCs in solid tumours

Macrophage differentiation and their role in tumourigenesis

Model of EphA/ephrin-A expression in GBM.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Presentation transcript:

An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal of Cancer (2014) 111, 817-822 doi:10.1038/bjc.2014.215 Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2014 Cancer Research UK.